Founder & CEO — AI-Driven Drug Discovery Pioneer in England

Drug discovery is broken. We're building the AI that fixes it: a closed-loop agentic system that does the scientific reasoning end to end and returns predictions you can trace back to the evidence behind them. We're looking for a founder and operator to join our technical and product founders. As Co-founder & CEO, you take a built, already-used platform from spin-out through a competitive seed round and on to Series A. The company spins out of Deep Science Ventures over the coming months.

THE OPPORTUNITY

Drug discovery is one of the most important problems in the world and one of the least solved. Biology is complex; the useful data is sparse; the work runs in slow cycles of trial and error. Teams spend years and billions of dollars on development, and most of the time the drug still fails. Brute force will not fix it: more compute and more data have not made biology predictable. Making today's process incrementally faster will not either, because that process is capped by what a human team can hold in their heads. What works is a different way of doing the science itself, an AI framework that reasons through it end to end, drawing on the published literature and the data and closing the loop with the wet lab. It's built around what today's agentic models are good at, and guarded hard where they fail. The proof of concept is ready and has been tested on several use cases. In a single run it processed an entire disease's single-cell data, ingested hundreds of experimental facts extracted from the literature, built a connected map of the biology and returned drug-target hypotheses. Each hypothesis came back marked supported or refuted, traceable with provenance to the exact evidence behind it. When the data is this thin, that grounding is what separates an answer you can build on from one you take on faith. The work came out of a collaboration with the Allen Institute, and the first results are submitted to a top-tier journal (Cell). The system already produces strong results for parts of the drug development pipeline, target validation among them, powered by the data modalities we have built in. The plan is to scale that to every modality and reach what the whole field is chasing: reliably predicting what a clinical trial will do before it runs, with a concrete explanation of the biology of why. We prove things with hard, contamination-free benchmarks rather than decks. We've built a freedom-to-operate benchmark for our internal tool and are working towards a clinical-trial benchmark with mechanistic explanation, because a trial is the one place biology gives a straight answer. An engine validated against that benchmark is more than capable of tackling every stage of drug development, and in time, of showing not just what a trial will do but how to change it. That's the mission. Not to make today's process a bit faster, but to change what is possible.

THE ROLE

This is a deeply hands-on role. As Co-founder & CEO, you own the commercial and company-building side from day one, working hand in hand with the other founders, who own the platform and the science between them. You will:

• Shape strategy and positioning alongside the founding team.
• Lead fundraising: run a competitive seed round and the path to Series A.
• Build the commercial side: partnerships, pilots and paying customers across pharma and biotech.
• Build the company: hiring, story, board, grants, academic partnerships and daily operations.

Location: Hybrid, UK-based · Commitment: Full-time from spin-out · Equity: Meaningful co-founder equity, milestone-linked.

WHO WE'RE LOOKING FOR

We're building an AI company that works on drug discovery, not a drug company that uses AI. The hard part is the reasoning system, and biology is where we point it. So the person we're searching for has their depth in AI. You've held a role with real ownership at one of the labs or companies at the front of the field, and the work you did there is known by name. Or you've built a company and raised the money for it yourself, on your own conviction. Either way, investors back you on your record alone. You might know very little biology, and that's okay. The science is held between the two founders. What we look for is a real curiosity about the biology, and the drive to learn it quickly from the people who already know it. You won't be building the platform; with the rest of the founding team, you'll set the strategy for what it's for and where it goes. If your depth is in the science rather than AI, and your name alone raises a round, everything else here still applies. Get in touch. Either way, these are essential:

• Your name is what makes the round raisable.
• You've either led a priced round yourself, or you carry the kind of track record that lets one be led.
• You hold your own in a room of scientists and a room of investors.
• You lead from the front.
• This is a founding seat, not a board seat and not an advisory one.
• You can go full-time from the spin-out.
• Location is flexible: the company is UK-based, but a US base and a US investor network are worth more to us than sitting nearby, so if you're in the US or elsewhere and can travel here often, say so in your first note.

Requirements

• Driven to build a category-defining company at the frontier of AI and drug discovery, and to challenge how the industry works today.
• Impact-driven: you take the initiative, make things happen, and think from first principles about what's really needed.
• Clear entrepreneurial spirit, with the ability to thrive in an ambiguous, unstructured and demanding environment.
• Collaborative by nature: able to partner closely with two founders, one technical and one product.

Experience (must-have)

• World-class expertise in AI, with real ownership behind it: not a seat at a famous lab, but work the field knows is yours.
• Deep drug-discovery experience can stand in its place if your name raises money, but AI is what we're searching for.
• Either you have personally led a priced round, or your name and track record make one raisable.
• Able to go full-time from spin-out.
• UK base preferred, but a strong US base and investor network count for more than location.
• Not building, and not recently building, a company on the same substrate: agentic reasoning, knowledge graphs and hypothesis generation for drug discovery.

Preferred experience (nice-to-have)

• Time at a frontier AI lab or a top AI-for-science company, in a role the field would recognise by name.
• A strong, transferable investor network in AI, deep tech, bio or health.
• Have scaled a company from seed to Series A and beyond.
• Commercial and business-development track record: partnerships, pilots, paying customers.
• Experience selling technical or scientific software into pharma, biotech or research institutions.

ABOUT DSV

Deep Science Ventures (DSV) is on a mission to create a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out, and invest in science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. Operating across Pharmaceuticals, Climate, Agriculture, and Computation, we tackle the challenges defining these areas by taking a first-principles approach and partnering with leading institutions.